New FDA-Approved Treatment for RKD

The FDA has approved Gazyva® (Obinutuzumab) for Primary Membranous Nephropathy (pMN). haga clic aquí for more information. Please visit our Patient Navigation tool for support.

RECURSOS

/

ENCUENTRA UN ESPECIALISTA

/

CONTACTO

Gazyva® (Obinutuzumab) for Primary Membranous Nephropathy

Obinutuzumab (brand name Gazyva) is a medication that targets certain immune cells involved in autoimmune diseases. It is already used to treat some blood cancers and lupus nephritis and is being studied as a treatment for primary membranous nephropathy (pMN). 

Primary membranous nephropathy (pMN) is a kidney disease in which the immune system mistakenly attacks part of the kidney’s filtering system. This causes protein to leak into the urine and can lead to swelling, low blood protein levels, and, in some patients, loss of kidney function over time. 

Obinutuzumab has shown promising results in clinical trials for pMN. As of October 2026, the FDA is reviewing its use for this condition.

Medically reviewed by Dr. Laith Al-Rabadi, MD 

 How does the medication work? 

Obinutuzumab works by targeting B cells, a type of white blood cell that helps the body make antibodies. In primary membranous nephropathy, the immune system produces antibodies that attack the kidney’s filtering units. These antibodies can damage the filters and cause protein to leak into the urine.

Obinutuzumab targets a protein called CD20 on the surface of B cells, leading to their removal from the body. By reducing these cells, the medication helps decrease the production of harmful antibodies and allows the kidneys time to recover.

Obinutuzumab works in a similar way to rituximab, another medication commonly used to treat membranous nephropathy. However, it is designed to produce more effective B-cell depletion and may help some patients who have not responded adequately to other treatments.  

How is the medication administered? 

Obinutuzumab is given through an intravenous (IV) infusion at a hospital or infusion center. 

In the MAJESTY clinical trial, patients received 1,000 mg on the first treatment day, followed by additional infusions approximately 2 weeks, 6 months, and 6½ months later. 

Before each infusion, patients receive medications to reduce the chance of an infusion reaction. The infusion is given under medical supervision, and patients are monitored during treatment. 

The exact treatment schedule for pMN will depend on the final FDA-approved prescribing information, if approval is granted. 

Is the medication right for me? 

Obinutuzumab may be an option for adults with primary membranous nephropathy who have significant protein loss in their urine and are at risk of progressive kidney damage. 

Not everyone with membranous nephropathy needs immunosuppressive treatment. Some patients improve with supportive care, including blood pressure control and medications that reduce protein loss in the urine. 

For patients with persistent or severe disease, treatment that targets the immune system may be needed. 

Your nephrologist will consider several factors before recommending treatment, including: a) The amount of protein in your urine, b) Your kidney function, c) Blood tests for antibodies associated with membranous nephropathy, such as anti-PLA2R, d) Previous treatments and how well you responded, and e) Your risk of infection and other medical conditions 

Obinutuzumab may be particularly useful for patients who need treatment directed at the immune system, although more research is needed to determine which patients benefit most. 

*Nota: La decisión de recetar un medicamento es responsabilidad de su médico/proveedor de atención primaria según la evaluación de su afección. Lo anterior está destinado únicamente a fines informativos. Discuta esta información y toda la información sobre drogas/medicamentos con su médico antes de comenzar o suspender cualquier medicamento.

Preguntas frecuentes

The MAJESTY trial was a large clinical study comparing obinutuzumab with tacrolimus, another medication used to treat membranous nephropathy. The study included 142 adults with primary membranous nephropathy and followed them for approximately two years. At two years, 37% of patients treated with obinutuzumab achieved complete remission, compared with 6% of patients assigned to tacrolimus. Complete remission means that protein loss in the urine has decreased to a very low level while kidney function remains stable. 

When complete and partial remission were considered together, approximately 51% of patients in the obinutuzumab group achieved remission, compared with 13% in the tacrolimus group. Obinutuzumab also produced a greater and more sustained reduction in the antibodies associated with membranous nephropathy. These findings are encouraging because achieving remission is an important goal of treatment and is associated with better long-term kidney outcomes. However, the study did not establish that obinutuzumab prevents kidney failure, and longer follow-up is needed. 

Obinutuzumab suppresses targeted parts of the immune system, which raises the risk of infection and requires structured monitoring. 

Infusion reactions (such as fever, chills, or flushing) are most common during the initial dose; premedications like corticosteroids, antihistamines, and acetaminophen are given beforehand to reduce this risk. 

Because the drug deeply clears B cells, it can cause hypogammaglobulinemia (a drop in protective blood antibodies) and late-onset neutropenia (a delayed fall in infection-fighting white blood cells weeks or months post-infusion). Routine blood draws track both. 

Vaccination timing is also critical: non-live vaccines should be administered at least 2 to 4 weeks prior to starting treatment, while live vaccines are strictly contraindicated during therapy and recovery. 

Patients must complete baseline screening for dormant infections like hepatitis B to avoid reactivation, and remain aware of rare viral risks like PML. 

In the MAJESTY trial, serious adverse events occurred in 17% of obinutuzumab patients versus 14% on tacrolimus, with serious infections remaining rare in both groups.

Different treatments work in different ways. 

Rituximab and obinutuzumab both target B cells, which are involved in producing the antibodies that cause membranous nephropathy. Obinutuzumab is designed to produce deeper B-cell depletion, but a large randomized trial directly comparing these two medications in pMN has not yet established that one is better than the other. 

Tacrolimus and cyclosporine help reduce protein loss by suppressing the immune system and affecting the kidney’s filtering cells. However, protein loss may return after these medications are stopped, and prolonged use can affect kidney function. 

Cyclophosphamide, usually combined with corticosteroids, can be effective in patients with severe disease but carries important risks, including infections, infertility, and other long-term complications. 

The choice of treatment depends on disease severity, kidney function, previous treatment, and individual risks. 

If the FDA approves obinutuzumab for primary membranous nephropathy, patients will be able to discuss this treatment with their nephrologist. Obinutuzumab is administered at an infusion center and requires a prescription and medical supervision. Insurance coverage, prior authorization requirements, and patient assistance programs may vary. Until FDA approval for pMN is granted, obinutuzumab may be available for this condition through clinical trials or off-label prescribing when a treating physician considers it appropriate. Patients interested in obinutuzumab should speak with their nephrologist about whether it is a suitable treatment option. 

Encuentre un especialista

Es importante trabajar con un nefrólogo que se especialice en enfermedades renales raras (ERR) y que pueda brindarle asesoramiento personalizado según sus necesidades de salud individuales y los cambios en los tratamientos disponibles. NephCure tiene una lista seleccionada de especialistas de NephCure en todo el país listos para ayudarlo.

Ensayos clínicos

Regístrese para recibir las últimas actualizaciones de NephCure.

INSCRIBIRSE
Este campo es para fines de validación y no debe modificarse.